CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) targeting programmed death-1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) have become one of the main therapeutic options for advanced non-small cell lung cancer (NSCLC).